| | |
|:---|:---|
| **Symbol** | SLC13A2 |
| **Full Name** | Solute Carrier Family 13 Member 2 (Na+-dependent sulfate/citrate transporter) |
| **Chromosome** | 17p13 |
| **NCBI Gene ID** | [10166](https://www.ncbi.nlm.nih.gov/gene/10166) |
| **OMIM** | [604202](https://www.omim.org/entry/604202) |
| **Ensembl ID** | ENSG00000166069 |
| **UniProt ID** | [Q9Y3D5](https://www.uniprot.org/uniprot/Q9Y3D5) |
SLC13A2 (NaS2) is a member of the SLC13 family of sodium-coupled dicarboxylate and sulfate transporters (NaDC). The transporter uses the energy of the sodium gradient to drive the uptake of dicarboxylates (citrate, succinate, malate) and sulfate ions against their concentration gradients. In the brain, SLC13A2 is expressed at the blood-brain barrier and in neurons, where it contributes to sulfate acquisition and energy metabolism.
SLC13A2 operates as an electrogenic symporter:
- Substrate Binding: Citrate or sulfate binds to the transporter in the extracellular space
- Sodium Coupling: 3 Na+ ions co-transport with each substrate molecule
- Conformational Change: The transporter undergoes conformational changes to move substrates into the cell
- Ion Gradient Utilization: The Na+ gradient established by Na+/K+ ATPase provides the energy source
SLC13A2 transports multiple substrates:
- Sulfate: Primary substrate; essential for sulfation reactions
- Citrate: Important for energy metabolism
- Succinate: Tricarboxylic acid cycle intermediate
- Malate: Energy metabolism and NADH production
SLC13A2 expression patterns:
- Kidney: Proximal tubule epithelium; reabsorption of filtered citrate and sulfate
- Intestine: Small intestinal epithelium; dietary sulfate and citrate absorption
- Brain: Blood-brain barrier endothelium, choroid plexus, neurons
- Liver: Low expression
- Lung: Moderate expression
SLC13A2 is implicated in AD through multiple mechanisms:
- Sulfate Homeostasis: Reduced sulfate availability affects brain sulfation reactions
- Citrate Metabolism: Altered neuronal citrate affects energy metabolism and acetyl-CoA production
- Amyloid Processing: Sulfate is required for proper protein glycosylation and trafficking
- Blood-Brain Barrier: SLC13A2 dysfunction may impair nutrient delivery to the brain
- Tau Sulfation: Sulfate is needed for proper tau glycosylation
SLC13A2 dysfunction may contribute to PD:
- Energy Metabolism: Altered citrate handling in dopaminergic neurons
- Sulfate Deficiency: May affect glutathione synthesis
- Mitochondrial Function: Citrate is important for mitochondrial metabolism
SLC13A2 mutations or dysfunction may contribute to:
- Neurological Deficits: Cognitive impairment
- Developmental Abnormalities: In severe cases
- Psychiatric Symptoms: In adult-onset cases
SLC13A2 at the blood-brain barrier is critical for sulfate delivery:
flowchart LR
A["Blood"] --> B["SLC13A2 on BBB"]
B --> C["Na+-coupled sulfate uptake"]
C --> D["CSF/Brain"]
Echoroid["Echoroid plexus"] --> D
F["Neurons"] --> G[Sulfate for:
- Protein sulfation
- GAG synthesis
- Lipid sulfation]```
SLC13A2-mediated citrate transport affects neuronal metabolism:
- TCA Cycle: Citrate enters mitochondria for energy production
- Acetyl-CoA: Citrate is a precursor for acetyl-CoA in lipid synthesis
- Anaplerosis: Citrate supports TCA cycle replenishment
- Beta-oxidation: Citrate affects fatty acid metabolism
Sulfate is essential for numerous brain functions:
- Protein Sulfation: Post-translational modification affecting protein function
- Glycosaminoglycan Synthesis: Heparan sulfate, chondroitin sulfate
- Lipid Sulfation: Sulfolipids in myelin
- Neurotransmitter Metabolism: Some neurotransmitter sulfates
SLC13A2 variants have been associated with:
- AD susceptibility in genome-wide studies
- PD risk in specific populations
- Response to folate treatment
- Loss-of-Function: Cause renal stone disease
- Expression Changes: Associated with aging and neurodegeneration
SLC13A2-based therapeutic strategies include:
- Enhancer Development: Small molecules that increase SLC13A2 activity
- Gene Therapy: Vector-mediated SLC13A2 delivery
- Sulfate Supplementation: Bypass SLC13A2 with sulfate delivery
- Biomarker Development: SLC13A2 expression as disease marker
- Patient Stratification: Based on SLC13A2 genotype
- Treatment Monitoring: Response to metabolic interventions
- Blood-Brain Barrier Penetration: Therapeutic delivery to brain
- Substrate Specificity: Targeting specific transport functions
- Homeostatic Regulation: Avoiding disrupting normal physiology
SLC13A2 interacts with multiple pathways: